| __timestamp | Neurocrine Biosciences, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 46425000 | 45967000 |
| Thursday, January 1, 2015 | 81491000 | 114737000 |
| Friday, January 1, 2016 | 94291000 | 183204000 |
| Sunday, January 1, 2017 | 121827000 | 231644000 |
| Monday, January 1, 2018 | 160524000 | 293998000 |
| Tuesday, January 1, 2019 | 200000000 | 357355000 |
| Wednesday, January 1, 2020 | 275000000 | 412084000 |
| Friday, January 1, 2021 | 328100000 | 497153000 |
| Saturday, January 1, 2022 | 463800000 | 705789000 |
| Sunday, January 1, 2023 | 565000000 | 648449000 |
| Monday, January 1, 2024 | 731100000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc. have demonstrated a strategic focus on R&D, with both companies significantly increasing their investments. From 2014 to 2023, Neurocrine Biosciences saw a remarkable 1,116% increase in R&D expenses, while Ultragenyx Pharmaceutical's spending surged by 1,310% during the same period.
By 2023, Neurocrine Biosciences allocated approximately 24% more to R&D compared to 2022, reaching a peak of $565 million. Meanwhile, Ultragenyx Pharmaceutical's R&D expenses slightly decreased by 8% from the previous year, settling at $648 million. This strategic focus on R&D underscores the companies' dedication to pioneering new treatments and maintaining a competitive edge in the biotech industry.
Analyzing R&D Budgets: GSK plc vs Neurocrine Biosciences, Inc.
Research and Development: Comparing Key Metrics for argenx SE and Ultragenyx Pharmaceutical Inc.
R&D Insights: How Teva Pharmaceutical Industries Limited and Neurocrine Biosciences, Inc. Allocate Funds
Comparing Innovation Spending: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Veracyte, Inc.
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.
R&D Insights: How Jazz Pharmaceuticals plc and Ultragenyx Pharmaceutical Inc. Allocate Funds
R&D Spending Showdown: Blueprint Medicines Corporation vs Ultragenyx Pharmaceutical Inc.
Amneal Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Ultragenyx Pharmaceutical Inc. and Vericel Corporation
R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs Xencor, Inc.